ORGANIZATION

• FPMAJ Official Prods Rethink of Off-Year Price Revision as Ukraine War Pushes Up Costs
  April 27, 2022

• JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
  April 27, 2022

• JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
  April 25, 2022

• Predictability of Drug Pricing Must Be Ensured: EFPIA Japan Director General
  April 22, 2022

• Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
  April 12, 2022

• FPMAJ Looks into Impact of Shanghai COVID-19 Lockdown
  April 11, 2022

• Asian Pharma Groups to Boost Drug Discovery Collab via RWD Use
  April 7, 2022

• Drug Damage Watchdog Calls for Temporary Suspension of Lagevrio Use
  April 6, 2022

• JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
  April 5, 2022

• Stop Avigan Stockpiling, Revoke Flu Approval: Drug Damage Watchdog
  April 5, 2022

• JPMA to Push Innovation Cycle, Ponder Next-Gen Pricing System: FY2022 Project Plan
  April 5, 2022

• Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
  April 4, 2022

• Generic Use Rate Treads Water at 79.3% in October-December: JGA
  April 4, 2022

• FPMAJ Poll Finds 65% Self-Inspection Rate for “Stable Supply Medicines”
  March 28, 2022

• FPMAJ Hammers Out FY2022 Project Plans, Revs Up for Off-Year Revision Debate
  March 28, 2022

• FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
  March 28, 2022

• JGA to Employ 3rd Party Auditor on Trial Basis to Ensure Manufacturing Compliance
  March 28, 2022

• Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
  March 25, 2022

• FPMAJ Launches Taskforce to Conduct Supply Surveys for 130 APIs
  March 25, 2022

• Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
  March 22, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• …
• Next ›
• 最終 »